Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow Post author:Sam Post published:November 29, 2017 Post category:BioPharma Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace You Might Also Like Kura Oncology To Report Fourth Quarter And Full Year 2016 Financial Results March 7, 2017 SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech November 16, 2017 Inscripta Snags $55.5 Million in Funding, Looks to Expand Employment February 27, 2018
